New hope for tough blood cancers: experimental drug HRS-3738 enters human testing
NCT ID NCT05363800
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called HRS-3738 in people with two types of blood cancer—non-Hodgkin's lymphoma and multiple myeloma—that have returned or not improved after prior treatments. The main goals are to find a safe dose and check how well the drug works. About 74 adults will take part across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT AND REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan cancer Hospital
Zhengzhou, Henan, 450000, China
-
Sheng Jing Hospital of China Medical University
Shengyang, Liaoning, 110004, China
-
Zhejiang University School of Medicine The First Affiliated Hospital
Hangzhou, Zhejiang, 310003, China